HomeCompareSMHD vs ABBV

SMHD vs ABBV: Dividend Comparison 2026

SMHD yields 84.39% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SMHD wins by $1.91M in total portfolio value
10 years
SMHD
SMHD
● Live price
84.39%
Share price
$2.37
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.01M
Annual income
$604,528.33
Full SMHD calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SMHD vs ABBV

📍 SMHD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSMHDABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SMHD + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SMHD pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SMHD
Annual income on $10K today (after 15% tax)
$7,173.00/yr
After 10yr DRIP, annual income (after tax)
$513,849.08/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, SMHD beats the other by $492,793.08/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SMHD + ABBV for your $10,000?

SMHD: 50%ABBV: 50%
100% ABBV50/50100% SMHD
Portfolio after 10yr
$1.06M
Annual income
$314,650.05/yr
Blended yield
29.74%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SMHD
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SMHD buys
0
ABBV buys
0
No recent congressional trades found for SMHD or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSMHDABBV
Forward yield84.39%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$2.01M$102.3K
Annual income after 10y$604,528.33$24,771.77
Total dividends collected$1.76M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SMHD vs ABBV ($10,000, DRIP)

YearSMHD PortfolioSMHD Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$19,139$8,438.82$11,550$430.00+$7.6KSMHD
2$35,573$15,094.30$13,472$627.96+$22.1KSMHD
3$64,283$26,219.99$15,906$926.08+$48.4KSMHD
4$113,065$44,281.87$19,071$1,382.55+$94.0KSMHD
5$193,769$72,790.25$23,302$2,095.81+$170.5KSMHD
6$323,920$116,586.40$29,150$3,237.93+$294.8KSMHD
7$528,739$182,144.59$37,536$5,121.41+$491.2KSMHD
8$843,617$277,866.52$50,079$8,338.38+$793.5KSMHD
9$1,317,010$414,339.81$69,753$14,065.80+$1.25MSMHD
10$2,013,729$604,528.33$102,337$24,771.77+$1.91MSMHD

SMHD vs ABBV: Complete Analysis 2026

SMHDStock

The investment seeks to provides a monthly compounded two times leveraged long exposure to the performance of the index, reduced by the accrued fees. The fund is a series of Monthly Pay 2xLeveraged Exchange Traded Access Securities (ETRACS) linked to the performance of the price return version of the Solactive US Small Cap High Dividend Index. The index is designed to measure the performance of 100 relatively small capitalization, dividend yielding index constituent Securities selected from a universe of qualifying U.S. listed stocks.

Full SMHD Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SMHD vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SMHD vs SCHDSMHD vs JEPISMHD vs OSMHD vs KOSMHD vs MAINSMHD vs JNJSMHD vs MRKSMHD vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.